The RPLND templates were either full bilateral, right modified, left modified, or a full left (Interaortocaval (IAC) þPara-aortic(PA) LNs). LN relapses after RPLND were assessed.
INTRODUCTION AND OBJECTIVES:
Given the rarity and complexity of inferior vena cava (IVC) thrombi, single center series describing surgical outcomes are typically small. Alternatively, large multicenter studies may lack granularity to change management approaches. Here we present our single center experience with radical nephrectomy and IVC thrombectomy.
METHODS: Retrospective chart review was conducted of all patients who underwent nephrectomy and IVC thrombectomy at a single institution between 1990 and 2018. Demographic information, laboratory results, intra-and postoperative details, and overall survival were captured from the electronic medical record (EMR). Social security death index was queried when mortality data was not available in the EMR. Descriptive statistics, chi-square and Fisher's exact tests, Kaplan-Meier curves and Wilcoxon tests were employed for data analysis.
RESULTS: From April 1990 to July 2018 409 patients underwent nephrectomy with IVC thrombectomy, of whom 281 were men (68.7%) and 128 were women (31.3%). Average age at time of surgery was 62 years. Intraoperative thrombus level was I in 59 patients (14.4%), II in 134 patients (32.8%), III in 115 (28.15%) and IV in 101 (24.6%). Most (94%) of surgeries were performed via a chevron incision, a thoracoabdominal approach was used in 10, and a robotic approach was used in 3. The IVC was repaired primarily in the majority of cases, 6 were closed with the aid of a bovine graft, 10 with Goretex, 2 with native pericardium, and in 20 cases the IVC was managed with ligation. 131 cases were done on cardiac bypass. Mean primary tumor size was 10cm (range 1.4 to 30 cm) and 289 (71%) of tumors were right sided. On final pathology 27% were node positive and 20% had metastatic disease. Ipsilateral adrenal invasion was identified in 18% of patients. Post-operative complications occurred in 149 (36.7%) of cases and reoperation and perioperative death each occurred in <5%. 30 day, 90 day, and 5 year mortality occurred in 6.3%, 12.0%, and 60.3% of patients, respectively. Level IV thrombus, as compared to levels I-III, conferred a higher risk of postoperative complication (55.0% v 30.4%, p <0.0001), intraoperative complication (14.0 v 6.7%), and perioperative death (14% v 2.93%, p[0.0001).
CONCLUSIONS: Renal neoplasm with associated IVC thrombus is a complex condition with high long term and perioperative morbidity and mortality. In this large single center series, level IV thrombus was associated with higher risk of short-term complications and mortality. METHODS: This retrospective study compared the progressionfree survival (PFS) and overall survival (OS) between mRCC patients who did or did not undergo CN. We screened out and enrolled patients from April 2006 to November 2013 as suitable candidates for CN with primary kidney tumor in situ. Logistic regression models were used to measure the effects of the clinical and pathological covariates. The Kaplan-Meier method and log-rank test were performed to evaluate the possible survival differences between two groups. RESULTS: 70 patients were assigned to undergo CN followed with sunitinib and 48 received sunitinib alone. According to the survival analysis, the median PFS was 8.38 months and the median OS was 15.48 months, with 109 deaths observed. There were no significant difference between CN-sunitinib group and sunitinib-alone group in both PFS(7.2 versus 11.6 months, 95% confidence interval, 5.3 to 11.8; P[0.525) CONCLUSIONS: Cytoreductive nephrectomy may offer no survival benefits in those mRCC patients with primary kidney tumor in situ, and moreover, sunitinib-alone therapy perhaps contributes longer PFS and OS for the patients with IMDC high-risk disease and those with lymphatic metastasis.
